Multivariate regression modelling provides a statistically powerful means of quantifying the effects of a given treatment while compensating for sources of variation and noise, such as variability between human donors and the behaviour of different peptides during mass spectrometry. However, methods to quantify endogenous post-translational modifications (PTMs) are typically reliant on summary statistical methods that fail to consider sources of variability such as changes in levels of the parent protein. Here, we compare three multivariate regression methods, including a novel Bayesian elastic net algorithm (BayesENproteomics) that enables assessment of relative protein abundances while also quantifying identified PTMs for each protein. We tested the ability of these methods to accurately quantify expression of proteins in a mixed-species benchmark experiment, and to quantify synthetic PTMs induced by stable isotope labelling. Finally, we extended our regression pipeline to calculate fold changes at the pathway level, providing a complement to commonly used enrichment analysis.
Introduction
Spiraling costs of drug/therapeutic development and a low probability of success have driven an increase in the use of models based on patient-derived material in an attempt to determine translational potential prior to clinical studies. However, unlike samples from genetically homogeneous, completely inbred model organisms, patient samples can possess substantial differences between individuals. This variability between samples can make discerning a statistically significant effect extremely difficult using the standard statistical methods commonly used in biology.
The lack of statistical power caused by poor signal-to-noise ratios in primary samples and the difficulty in obtaining large donor cohorts can compromise potentially promising biological studies, resulting in wasted time and prohibitive expenditure.
The problem of high inter-individual differences is rarely more acute than in high-throughput omics experiments. The difference between patient samples is particularly evident in omics experiments where subtle differences in the levels of individual features within samples (e.g. transcripts, peptides derived from proteins, etc.) are compounded over many such features, demonstrating quantifiable inter-individual differences even between genetically identical twins (Brodin et al, 2015) . This is especially relevant to typical mass spectrometry (MS) proteomic methods wherein quantities associated with multiple features (i.e. peptides) are used in the calculation of a fold change for a single protein.
In bottom-up MS-based proteomics, proteins are enzymatically digested into peptides and the abundances of these individual peptides are used to derive protein quantifications. A core assumption is that peptide abundance is proportional to protein abundance. However, each peptide has different physico-chemical properties that mean they each behave differently during sample preparation or within the mass spectrometer itself. For instance, residues surrounding cleavage sites can affect efficiency of enzymatic digestion (Rodriguez et al, 2008; Lawless & Hubbard, 2012) ; some peptides ionise less efficiently than others (Abaye et al, 2011) and in data-dependent analysis, peptides of similar mass-to-charge (m/z) ratios may compete during co-elution or ionisation (Schliekelman & Liu, 2014) , potentially biasing the peptides finally detected. These discrepancies can be exacerbated by biologically relevant post-translational modifications (PTMs) that alter the behaviour of individual peptides, resulting in substantial differences in measured intensities for peptides that belong to the same protein, even in purified protein samples. Even with normalisation, differences in the behaviour of individual features between donors and experimental treatments are difficult to account for.
It was recently shown that combining MS datasets from multiple fractions and extraction conditions could achieve near-complete coverage of the human cell proteome, including >14000 protein isoforms (Bekker-Jensen et al, 2017) . Interestingly, the same study also identified ~10000 phosphorylation sites and ~7000 acetylation sites without specific enrichment. New sample preparation techniques and the increasing sensitivity of MS instrumentation have increased coverage of PTMs. However, with this increase in sensitivity comes the problem of resolving differential regulation of different forms of the same protein (proteoforms), as not all peptides belonging to a given protein respond in the same way to a given treatment, an assumption made by many commonly used quantification methods.
Common statistical methods for dealing with variability include the summarisation of peptide intensities using averages, sums or medians to give subject-level protein quantification (Goeminne et al, 2015) . However, these subject-level summary models fail to account for differences in behaviour of peptides belonging to the same protein during analysis, and thus are prone to perturbation by outlier peptides. They are also highly dependent on obtaining large numbers of peptides from each protein and thus can suffer from low statistical power when analysing less extreme fold changes in small or low abundance proteins (e.g. transcription factors). To address this, previous statistical models have focused on exclusion of outlier peptides to improve protein quantification (Forshed, 2013; Swift et al, 2013a) , at the cost of a loss of information relating to different proteoforms for a given protein; or have attempted to deduce differences in the abundance of peptides belonging to different sub-populations of the same protein (Henao et al, 2012 (Henao et al, , 2013 Webb-Robertson et al, 2014; Zeng et al, 2017) .
For proteomics, linear regression models represent a powerful means of teasing apart different, known sources of variability in peptide intensities, with the aim of returning the variability caused by a given experimental condition. Linear modelling has become the standard for transcriptomic analysis thanks to the widely used LIMMA package (Smyth, 2004) and has been successfully adapted for MS data analysis. For example, in the peptide-based model proposed by Choi et al. (2014) with donor effects added:
Where, for a given protein, ! !"# (the response variable) corresponds to the observed log 2 intensity However, peptide-based linear models can be prone to overfitting, wherein predictive power is lost as the model attempts to fit the noise within the data rather than any overall trends. This may be due to the effects of outlier peptides, such as those that possess a biologically relevant PTM with a fold change different to that of its parent protein, or simply due to peptide mis-identification. The effects of outlier peptides on the final linear model fit can be mediated by various weighting strategies (e.g. see Goeminne et al. (2016) ). However, for modelling changes in PTM abundance, it would be useful to obtain effect sizes for peptides that specifically interact with a given treatment and separate them from effect sizes for other parameters that may be interacting with these peptides. Linear modelling is more flexible than the name suggests and can also handle interactions between predictor variables; for example, where an experimental condition has an effect on the intensity of an individual peptideindependent of its effect on the protein as a whole -possibly due to some biologically important PTM of that specific peptide. For example, we can extend the model in (1) to allow separation of peptide:treatment and peptide:donor effects in studies using primary human samples, as in (2) (see also the model in (Clough et al, 2009) ).
Wherein ! !"# corresponds to the intensity of peptide f, in experimental group g, from protein i, extracted from technical replicate r of donor d. The !s correspond to the fitted coefficients for each predictor variable. Note the interactions coefficients ! !:! , and ! !:! in (2), denoting variability in individual peptide intensities, f, caused by the experimental treatment g or largely unknown features of the individual donor d. From here on we refer to (1) as linear and (2) as non-linear.
Unfortunately, overfitting becomes particularly acute in models that attempt to deal with many potential sources of variability, some of which may interact or correlate with one-another, and where the number of parameters to be estimated exceeds the number of observations. The inclusion of interaction terms in a model has potential to provide important biological insight regarding different isoforms and PTMs of a given protein (collectively called proteoforms) -vital mechanisms of posttranslational regulation of cellular function. However, interaction terms may not be necessary for all proteins in a dataset and the decision whether or not to include them would need to be made on a protein-by-protein basis.
Simpler models (e.g. those used by (Choi et al. (2014) and (Goeminne et al. (2016) ) minimise the potential for overfitting found in more complex models. However, when many potential sources of variability exist it may be necessary to fit increasingly complex models wherein the choice of terms included, particularly any interaction terms, may need to be decided on a protein-by-protein basis.
Failure to select the correct terms could result in models failing to fit correctly, or even at all, especially if complex interaction terms are included when not needed. However, not including these terms may mean that subtle differences in peptide behaviour that occur only in specific proteins may go unaccounted for, resulting in a loss of accuracy. Thus, a means of automatically selecting appropriate features from a more complex model for use in fitting a final, sparse model is necessary.
Regularisation can be employed to minimise overfitting and perform feature selection. Regularisation involves attaching penalty weights to each coefficient (!), minimising its contribution to the final fit.
The nature of the penalty can differ depending on the type of Regularisation used. In the ridge regression algorithm used by Goeminne et al. (2016) an "L 2 " penalty is applied wherein !s are shrunk according to their squared norm, minimising the contribution of less important coefficients in explaining the total model variance. Although ridge regression shrinks coefficient estimates down to emphasise the most important !s, all !s remain non-zero. Another form of Regularisation is LASSO (least absolute shrinkage and selection operator), which shrinks !s according to their "L 1 " absolute norm. With LASSO, some !s can be set to exactly zero, excluding them from the model and giving rise to so-called "sparse" solutions. Several variations of these methods have been proposed, including an "elastic net" variation that combines properties of both ridge regression and LASSO to perform both model selection and shrinkage of remaining non-zero !s (Zou & Hastie, 2005) . These frequentist Regularisation methods have Bayesian parallels depending on the prior distributions the ! posteriors are sampled from, with L 2 Regularisation being equivalent to sampling of ! s from a Gaussian distribution, L 1 being equivalent to sampling from a Laplace (double exponential) prior and the elastic net being equivalent to ! sampling from an intermediate distribution (Bornn et al, 2010) .
Here we develop a Bayesian elastic net algorithm to provide regularised protein-specific models (BayesENproteomics), taking into account potential donor variability and interactions between specific peptides and experimental treatments and/or donor effects. This has the advantage in implicitly allowing for any individual peptide to behave differently from its identified protein group in response to treatment or donor effects. This means that BayesENproteomics does not assume that peptides have been identified correctly -a point we enforce by incorporating observation weights based on peptide identification confidence. However, unlike previous Bayesian regression models that attempt to accommodate variable peptide behaviour within a protein (Henao et al, 2012 (Henao et al, , 2013 Webb-Robertson et al, 2014) 
Results
BayesENproteomics shows increased sensitivity and accuracy in estimating protein fold changes compared to other regression models
To produce a benchmark dataset with known (ground truth) fold changes, peptides prepared from primary human mesenchymal stem cell (MSC) lysates and female C57BL/6J mouse skin were mixed in ratios of 3:1, 1:1 and 1:3 and analysed with a Q Exactive HF mass spectrometer ( Figure 1A ). Mixed species datasets have been used previously to validate protein quantification methods (Swift et al, 2013a) , but the method has practical applications, such as when quantifying protein content in xenograft models (Swift et al, 2013b; Ivanovska et al, 2017) . Mixed mouse/human samples provide a difficult problem for prospective quantification algorithms as approximately 70% of tryptic peptides are shared between mouse and humans and thus have to be discarded to obtain estimates for specific proteins. This meant that the quantification algorithms examined here had a limited number of observations with which to work. Secondly, the dynamic range of absolute protein abundances was derived from actual biological samples and so provided an accurate report of the error associated with estimating fold changes in low abundance proteins. Finally, this experiment yielded twin datasets (mouse and human); one with pronounced donor-donor variability (human cells) and one where all animals had the same genotype and environment (mouse skin), and so could be adequately explained by the model in equation (2) without donor effects. We reasoned that an algorithm that could account for donor-donor variability should be as accurate on the human dataset as on the mouse dataset.
Logged signals from species-unique peptides were normalised to the medians of the opposite species-unique peptides to provide the observed log 2 ratios used in quantification. To automatically select appropriate β parameters it was possible to employ Regularisation strategies such as ridge, LASSO or elastic net regression to select the best set of βs by shrinking unimportant βs to zero ( Figure 1B ). As LASSO has been shown to lack consistency when selecting from several correlated βs, we chose to use elastic net-based Regularisation as the introduction of L 2 Regularisation has been shown to introduce consistency to LASSO estimates by inducing grouping of correlated βs (Zou & Hastie, 2005) . However, the standard formula for calculating standard errors (SE) of β estimates Figure   1C ). Examples of the resulting chains are shown in Figure 1D and demonstrate good mixing and exploration of the posterior distributions.
MCMC-based methods can be used to deduce any unknown value, including missing values in proteomics experiments, provided appropriate conditional distributions can be provided. We used this property to sample from two prior distributions depending on whether a missing value was determined to be missing at random (MAR) or missing non-randomly (MNR) by logistic regression (adaptive multiple imputation (AMI); see Materials and Methods section for more details). As the majority of missing values in bottom-up proteomics are assumed to be left censored, it is common to perform imputation by sampling from a down-shifted Gaussian distribution (DGD). Missing values that were imputed separately for each protein by AMI possessed a similar overall distribution to those imputed from a DGD as in Tyanova et al (2016) , but with a greater number of values closer to the observed MS1 intensity mean, as expected ( Figure 3A shows estimation of log 2 fold changes for non-differentially abundant proteins in pairwise comparisons between three technical replicates from the same (mouse skin) sample, comparing the BayesENproteomics algorithm with ordinary least-squares (OLS) and linear mixed-effects (with Huber residual weights, LME-H) models (see Structured Methods section). All methods correctly determined log 2 fold change values clustered around zero and that almost no changes reached statistical significance (p-value of false discovery, with Benjamini-Hochberg correction, BHFDR < 0.05). In contrast, estimation of differentially abundant mouse ( Figure 3B ) and human ( Figure 3C ) proteins in our mixed human:mouse dataset showed larger variation in observed fold change values, with a number of proteins giving consistently incorrect fold change directions, regardless of the regression method. OLS and LME-H models had difficulty detecting any significantly differentially abundant proteins for expected fold changes < 3. In contrast, BayesENproteomics correctly identified more proteins as significantly differentially abundant in all comparisons ( Figure 3B , C). Importantly, fold change estimates calculated by BayesENproteomics possessed lower mean squared deviation from ground truth compared to those from OLS and LME-H ( Figure 3D ). Regularisation and weighting of residuals in LME-H did not markedly improve accuracy of fold change estimates compared to standard OLS models, although this may be due to the more complex model (2) that LME-H was required to fit ( Figure 3D ). BayesENproteomics showed decreased coefficient of variance (CV) values for differentially abundant proteins in the mixed human:mouse dataset compared to both OLS and LME-H ( Figure 3E ).
BayesENproteomics correctly detects increases in stable isotope-labelled proteoforms following PNGase F treatment in H 2 18 O
Protein function and activity is strongly determined by diverse PTMs, giving rise to different proteoforms within a given protein population. MS-based proteomics represents a powerful means to systemically interrogate changes in PTM abundance. However, determining relative PTM fold changes from PTM'd peptide abundance is dependent on accurate protein quantification . While it is possible to calculate protein abundance from only unmodified peptides, this ignores the fact that some proteins are constitutively modified as part of their normal maturation pathway (e.g. many extracellular matrix proteins are heavily glycosylated prior to secretion) and excluding these PTM-containing peptides from protein quantification would exclude a large proportion of all proteoforms present for that protein. While methods have been developed to analyse individual proteoform abundance in multiplexed, labelled experiments (Malioutov et al, 2017) , labelling is not always feasible and methods for quantifying differentially abundant PTMs in label-free experiments lag behind. Furthermore, while an ideal scenario would be to directly compare modified to unmodified peptide ratios (Tsai et al, 2017) , this is not always achievable in label-free proteomics of complex samples. While linear regression modelling has been shown to impart greater power and accuracy to protein quantification compared to summary statistical methods (Goeminne et al, 2015) , applying it to study PTMs is difficult due to the requirement for complex non-linear models that may be subject to overfitting.
To interrogate how well the three models implemented here were able to detect differentially abundant PTMs, we developed a benchmark dataset using PNGase F to introduce a stable isotope ( Figure 4B ). This analysis showed that more 18 O-labelled peptides were identified in the PNGase F-treated samples than controls, which contained 79 N-linked peptides presumably from spontaneous non-enzymatic deamidation. We expected that most spontaneously deamidated peptides would be unaffected by PNGase F treatment and that we would only observe an increase in relative 18 O-peptide abundance or parent 18 O-protein abundance for PNGase F-responsive peptides.
Furthermore, as spontaneous deamidation can occur to both Q and N residues, resulting in 18 O-E and 18 O-D residues, respectively, while PNGase F catalyses only deamidation of N-linked glycosylation sites, comparison to fold changes of Q-linked deamidation provided an ideal negative control.
To detect differentially abundant PTMs we employed three statistical methods. The first was a simple summary statistical extension to the OLS protein quantification method wherein log 2 fold changes for donor-normalised PTM'd peptide intensities were normalised to the log 2 fold changes of their parent protein (calculated by OLS). The second involved using the ridge regression performed by LME-H to fit the non-linear model described in equation (2) where peptide:group and peptide:donor interaction βs were entered as random intercept terms to limit overfitting. Finally, we used BayesENproteomics to fit the non-linear model described in (2) to calculate PTM fold changes. From simple cell lysates, following PNGase F treatment without enrichment we found 261 18 O-labelled sites (180 N-linked, 81
Q-linked) in 172 proteins when samples from all groups were aligned and search together.
Histograms in Figure 4C showed that OLS (top-left) and LME-H (middle-left) could not discern an 
Pathway analysis using linear modelling (PALM)
Theoretically, modelling pathway activity as a function of protein abundances (PALM; Figure 5A ) can have several advantages over classical pathway over-representation analysis. Firstly, the PALM approach proposed here utilised the entire dataset and so was not affected by potentially arbitrary statistical cut-offs used in defining 'interesting' and 'background' sets for over-representation analysis of proteins, similar to more recent enrichment analysis tools (reviewed in Huang et al., 2009 ).
Secondly, PALM used additional information regarding the direction and magnitude of fold changes and the error regarding their estimation to provide an overall estimate of how a given pathway behaved based on information available in a given dataset. Finally, PALM provides pathway-level fold change and error estimates, facilitating pathway-level clustering in complex, multi-treatment or timeseries datasets to gain a better "bird's-eye view" of what's happening in a dataset.
Figures 5B and 5C
show volcano plots assembled from Reactome (Fabregat et al, 2018; Milacic et al, 2012) pathway quantification from the human:mouse mixed species dataset based on protein-level output from OLS, LME-H and BayesENproteomics. While the magnitude of pathway-level log 2 fold changes was typically not equal to their protein components due to being inferred from relatively fewer observations and down-weighted according to uncertainty in initial protein fold change estimates (always > 0), directionality was conserved leading to an estimate of whether that pathway significantly increased or decreased. Pathway significance rose in accordance with the magnitude of their component protein fold changes (Figures 5B, C) .
Discussion
Multivariate regression methods represent a powerful means to deconvolute sources of variance in complex experiments. Here we attempted to design a statistical method that was able to accurately quantify protein and PTM fold changes in label-free proteomics experiments performed on heterogeneous primary human samples. Others have previously shown the superiority of linear regression-based effect size estimates over summary statistics (Goeminne et al, 2015; Clough et al, 2009 ). Here we outlined a weighted Bayesian regression algorithm with elastic net regularisation (to cope with differentially abundant PTMs as well as the high variability (and generally low availability) of samples from human donors, while still maintaining high interpretability of the resulting models ( Figure   6 ). In particular, BayesENproteomics incorporates an "adaptive" missingness mechanism that attempts to determine whether a value is MAR or MNR. Missing value imputation is performed as part of the Gibb's sampler and is thus unfortunately not available as a standalone component. In addition,
we utilised a novel weighing method that took into account confidence in peptide identification to improve quantification accuracy. We demonstrated the accuracy and specificity of the algorithm using serial mixed species datasets and stable isotope labelling using peptides obtained from multiple human donors.
Characterisation of complex samples is notoriously complex due to ionisation suppression and detection masking by peptides with similar m/z ratios often leading to missing values and underestimation of larger fold changes (this study and Goeminne et al. (2016) ). The mixed species dataset used here represented an especially difficult case with most (~70%) peptides rendered unusable due to being shared between the two species. While all methods tended to underestimate fold change magnitude (likely due to conflicting peptides in data-dependent analysis, exacerbated in mixed species analysis), we showed that BayesENproteomics was better able to confidently identify differentially abundant proteins and PTMs than simpler regression methods with greater accuracy in fold change estimates compared to OLS and LME-H regression models.
We used the iterative nature of MCMC processes to incorporate multiple imputation of missing values into protein fold change quantification. This eliminates the need for separate imputation and quantification steps and allows final fold change error estimates to take into account the intrinsic uncertainty regarding imputation of missing values (Schafer and Olsen, 1998 Finally, we extended our linear modelling pipeline to encompass pathway analysis. In transcriptomics experiments it is common to achieve coverage of the entire transcriptome (> 20000 transcripts in a given human cell/tissue), where hundreds to thousands may be differentially regulated in response to any given treatment. These large numbers make over-representation analysis using χ 2 or Fisher's exact tests well-suited to analysing differentially regulated transcriptomic processes. In contrast, proteomics experiments typically cover only a fraction of the total proteome (< 3000 proteins out of a potential > 20000 in a given human cell/tissue, increased further when considering multiple proteoforms) where only a hundred or fewer proteins may be differentially regulated, making it difficult to discern statistically significant process enrichment and erroneously giving the impression that "nothing is happening", often despite obvious morphological or metabolic changes assessed by other methods. Attempting to model pathway-level changes as a function of component parts for transcriptomics has previously shown that incorporating fold change estimates can increase specificity for discriminating pathway-level changes (Ozerov et al, 2016) . Although, it should be noted that the aim with PALM is not biomarker discovery (for which more stringent statistical cut-offs are needed) but rather to simply distil a complex dataset with many proteins down to fewer, more readily understandable pathways by assessing what processes are represented and what they do in response to a given treatment. This works similar to previous enrichment tools (e.g. PANTHER (Mi et al, 2017) ) and is similar to previous implementations of Bayesian regression in proteomics (Henao et al, 2013) , however here we opt to maintain interpretability by utilizing curated protein-pathway annotations when picking proteins to use in pathway-level model fitting. Here we chose to use Reactome pathway annotations (Fabregat et al, 2018) , but alternative categorical annotations could be used if desired. We believe that PALM provides a way of compressing information from many protein/proteoform fold changes into fewer annotated pathway fold changes, aiding interpretation of complex, multi-dimensional datasets. PALM can be used as a standalone pathway analysis tool; though it does assume protein fold changes are formatted according to the BayesENproteomics protein-level output format (see examples on the GitHub page).
With the improvement of MS technology, and the production of highly efficient unconstrained searching algorithms (Kong et al, 2017; Devabhaktuni et al, 2018) , 
Structured Methods

Reagents and Tools
Methods and Protocols
Cell culture
For the mixed species benchmark experiment, primary human mesenchymal stem cells (MSCs) were isolated from the bone marrow (knee and hip) of a single donor with informed consent and ethical approval, using established protocols (Strassburg et al, 2010) . All experiments were performed in accordance with relevant guidelines and regulations, and with National Research Ethics Service and University of Manchester approvals. MSCs were cultured on tissue culture treated polystyrene (TCTP) in low-glucose DMEM with pyruvate (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS, Labtech.com) and 1% penicillin/streptomycin cocktail (PS, Sigma-Aldrich).
Preparation of primary human MSCs lysates
Cells were lysed in 25 mM ammonium bicarbonate (AB) buffer containing 1.1% sodium dodecyl sulfate (SDS, Sigma), 0.3% sodium deoxycholate (Sigma), protease inhibitor cocktail (Sigma), phosphatase inhibitor cocktails (Sigma). Six 1.6 mm steel beads (Next Advance) were added to the tube and samples were homogenised with a Bullet Blender (Next Advance) at maximum speed for 2 minutes. Homogenates were cleared by centrifugation (12 °C, 10000 rpm, 5 minutes).
Preparation of mouse skin lysates
Skin from 3 month old female C57BL/6J mice was a gift from the Hardman group (University of Manchester; all animal work was performed under UK Home Office and local ethics committee approval). Ventral skin was shaved and scraped, then dissected into 1 mm 3 pieces. 100 µL of 8 M urea (Fisher Scientific) in 25 mM AB containing 25 mM dithiothretol (DTT, Sigma), protease and phosphatase inhibitor cocktails (Sigma) was added to the tissue sections with six 1.6 mm steel beads (Next Advance). Samples were then homogenised with a Bullet Blender (Next Advance) at maximum speed for 3 minutes. Resulting homogenates were cleared by centrifugation (12 °C, 10000 rpm, 5 minutes).
Preparation of tryptic peptides
Immobilised trypsin beads (Perfinity Biosciences) were suspended in 150 µL of digest buffer (1.33 mM CaCl 2 , Sigma, in 25 mM AB) with 50 µL of cell or tissue lysate and shaken at 1400 rpm overnight at 37 °C in a thermocycler. The resulting digest was then reduced by the addition of 4 µL of 500 mM DTT (Sigma, in 25 mM AB; 10 min. shaking at 1400 rpm at 60 °C) and alkylated by the addition of 12 µL 500 mM iodoacetamide (Sigma, in 25 mM AB; 30 min. shaking in the dark at room temperature).
Immobilised trypsin beads were removed by centrifugation at 10000 rpm for 10 min. Supernatant containing reduced, alkylated peptides were transferred to 1.5 mL 'LoBind' Eppendorf tubes and acidified by addition of 5 µL 10% trifluoroacetic acid (TFA, Sigma) in water, and cleaned by two-phase extraction (3 x addition of 200 µL ethyl acetate, Sigma, followed by vortexing and aspiration of the organic layer). Peptides were desalted using POROS R3 beads (Thermo Fisher). Briefly, R3 beads 
Preparation of serial mixtures of human and mouse peptides
Primary human MSCs and mouse skin sections were prepared separately as described above. Tryptic peptides from each preparation were mixed in ratios of 3:1, 1:1 and 1:3 (human:mouse, one series for each human donor:mouse), as described previously in (Swift et al, 2013a ).
Stable isotope labelling of peptides
Desalted peptides were resuspended in 100 mM AB dissolved in H 2 18 O with or without 5 U PNGase F (Sigma), to a final volume of 10 µL. Peptides were then incubated in a thermocycler (1400 rpm, 37 °C)
for 5 hours before drying down to a minimal volume in a vacuum centrifuge and resuspension in injection solution prior to MS analysis.
Mass spectrometry (MS)
Digested samples were analysed by liquid chromatography (LC) coupled tandem MS (LC-MS/MS)
using an UltiMate® 3000 Rapid Separation LC system (RSLC, Dionex Corporation) coupled to a Q Exactive HF (Thermo Fisher), peptide mixtures were separated using a multistep gradient from 95% A (0.1% formic acid, FA, Thermo Fisher, in water) and 5% B (0.1% FA in acetonitrile) to 7% B at 1 min, 18% B at 58 min, 27% B at 72 min and 60% B at 74 min at 300 nL/min, using a 75 mm x 250 µm i.d.
µm CSH C18, analytical column (Waters). Peptides were selected for fragmentation automatically
by data dependent analysis.
Preliminary data analysis using Progenesis QI (Nonlinear Dynamics)
Spectra from multiple samples were automatically aligned using Progenesis QI with manual placement of vectors where necessary. Peak picking sensitivity was set to 4/5 and features with a charge greater than +4 or fewer than 3 isotopes were excluded from further analysis. In the mouse/human mixed-species experiment, remaining features were searched using Mascot (Matrix Science), against the SwissProt and TREMBL pan-mammalian database (non-human and non-mouse identifications were removed). The peptide database was modified to search for alkylated cysteine residues (monoisotopic mass change, +57. 
Multi-variate regression modelling
To compare different types of regression analysis we used three different types of linear regression algorithms: (A) ordinary least squares (OLS); (B) Linear mixed effects models with Huber residual weights (LME-H); and (C) BayesENproteomics. Further details and references for each method are provided in the following sections. All analysis was performed using code written for Matlab R2015a (The MathWorks Inc).
Imputation of missing values
For OLS and LME-H methods, imputation of missing values was performed using a single imputation strategy whereby missing values are randomly sampled from a Gaussian distribution, downshifted to accommodate previous observations showing that missing values are more likely to be missing due to low abundance (Goeminne et al, 2016) . Briefly, for each peptide, minimum non-missing peptide intensities were averaged to model the centre of a normal distribution with a width equal to 0.3 times that peptide's σ (standard deviation). The mean (i.e. centre) of this normal distribution was negatively shifted by 1.6σ to model low abundance missingness, as described by Tyanova et al. (2016) Previous observations, such as by Tyanova et al. (2016) , have shown that imputation from a downshifted Gaussian distribution may be more suitable for imputation of missing peptide intensities from low abundance proteins, which are likely to be "missing non-randomly" (MNR), than for missing values from high abundance proteins, which are more likely to be "missing at random" (MAR) (Goeminne et al, 2015) . However, others have suggested that the type of "missingness" (MAR or MNR) that
predominates within a given dataset should decide what imputation strategy is used. For
BayesENproteomics, we employed a logistic regression-based model similar to that employed by Li et al. (2011) to discern whether a given missing value was MAR or MNR. Briefly, a model of "missingness" was first created to differentiate observations that were MAR from those that were MNR as in (3).
Where ! ! represents a binary vector for protein q with elements ! ! , … ! ! denoting whether an observation was missing (! ! = 1) or not (! ! = 0) and Z ! represents the logit transform of R ! to enable estimation of regressor coefficients ! using linear regression. As Z !" ∈ −∞, +∞ , we set minimum
and maximum values for Z ! to -10 (corresponding to a probability for observation ! being missing, ! ! < 0.00005 ) and 10 (! ! > 0.99995 ). ! ! and ! ! represent binary design matrices denoting the peptide (f) and treatment group (g) from which a given observation is derived.
vector of regressor coefficients; ! ! and ! ! represent the number of elements in ! ! and ! ! , respectively. ! ! and ! ! denote whether observations from a given peptide or treatment correlate with values in ! ! (i.e. whether probability of "missingness" increases when looking at intensities from particular peptides or from particular experimental treatment groups). The intercept term, ! ! denotes the intrinsic probability of missingness for that protein. We assume that most missing values in any proteomics experiment are MNR, an assumption that others have shown is valid (Karpievitch et al, 2012; Goeminne et al, 2016) . Therefore, if ! ! > ! ! and ! ! > 0 we inferred that missing observations associated with ! ! were MNR, and MAR otherwise. MAR and MNR missing values were imputed as part of each Gibbs sampler iteration as in (4) and (5).
Where (Schafer & Olsen, 1998) rather than fixed point estimates as in OLS and LME-H, where single random samples could strongly influence individual protein fold change estimates.
Weighting of residuals based on confidence of peptide identification
Identification of PTM'd peptides was performed by the inclusion of variable modifications during peptide database searching. Inclusion of multiple variable modifications was found to increase the peptide false discovery rate (FDR). The number of false-positive identifications was reduced by discarding peptides with low Mascot scores using a standard FDR cut-offs based on identification pvalues. We employ a Benjamini-Hochberg FDR (Benjamini & Hochberg, 1995) cut-off of < 0.2.
BayesENproteomics also employed a novel heuristic outlier weighting scheme that weighted against outlier peptides (which may possess biologically relevant PTMs), particularly if confidence in their identification was low. In this case we used Mascot scores as our indicator for peptide identification confidence. Firstly, Mascot scores, ! ! ..., ! ! were scaled by dividing them by a modified Bonferroni-like cut-off (similar to that described on the Mascot website, http://www.matrixscience.com/help/interpretation_help.html, accessed 23/10/17) and adjusted so that all the highest scoring peptides were weighted equally, as in (6) with values between 0 and 1.
, N = total peptides in dataset.
During each iteration of the Gibbs sampler, an n-dimensional vector of weights, ! with elements ! ! ..., ! ! , was calculated using a variation of the automatic outlier detection and weighting method in (Ting et al, 2007) . Initially, there was no a priori reason to exclude -or diminish the influence of -peptides that have passed the initial FDR screen. Instead, we opted to weight in favour of those peptides that either have high Mascot scores or low residuals (7). Transformed Mascot scores in ! were used to parameterize a binomial distribution giving ! that would determine if observations from that were favourably weighted each Gibbs sampler iteration (8).
Where ! is a vector of residuals with elements ! ! … ! ! , ! = ! − !! . Observations were then weighted by multiplying each row of ! and each value of ! by their respective weight calculated in (7), (9) and (10).
Where ! and ! are the weighted design matrix and response vector, respectively.
Linear regression implementation
Peptide-based linear regression modelling has previously been shown to possess greater statistical power and accuracy than summarization models when detecting differentially abundant proteins (Goeminne et al, 2015) . Here we compare three different models for calculating differentially abundant proteins and PTMs:
Ordinary least squares (OLS):
Differential protein abundance was calculated using the simple linear model (Choi et al, 2014; Clough et al, 2009) shown in (1), using the fitlm Matlab function. For calculating differential PTM abundance, the log 2 fold change for each PTM'd peptide was normalised to the log 2 fold change calculated for parent protein abundance. In cases where a single PTM site was shared by 2 or more peptides (i.e. missed cleavages), the most abundant one was used.
Linear mixed-effects models with Huber residual weights (LME-H):
The ridge regression/mixed-effects algorithm developed by Goeminne et al. (2016) , wherein peptides were modelled as random effects (i.e. they were assumed to be randomly sampled from a larger population and that they accurately modelled the variance of that population) using the more complex model shown in equation (2). Goeminne et al. (2016) exploited the link between ridge regression and mixed effects models to assign each ! ! a specific penalty, ! ! (where
. We recapitulated this algorithm using the fitglme Matlab function, including Huber weighting of residuals. To calculate changes in PTM abundances, peptide:group and peptide:donor interaction effects (! !:! , and ! !:! in (2), respectively) were included as random effects with the size of the resulting interaction !s denoting changes in the abundance of that peptide in response to treatment or donor effects, respectively.
BayesENproteomics:
This method utilises a novel Bayesian linear regression algorithm with elastic net Regularisation based on the hierarchical model detailed by Kyung et al. (2010) . Bayesian methods employ
Regularisation based on the prior distribution parameters were estimated from, with elastic net
Regularisation being equivalent to sampling from an intermediate Gaussian/Laplacian prior. Sampling was performed using a Gibbs sampler with the maximum number of iterations for each protein set at 25 × !"#$ + ! ! (runs = total number of MS runs to be analysed, ! ! = number of peptides), or 1,000 -whichever was higher -with half of these as burn-in iterations. The full hierarchical model for a single protein is detailed in equations (11)- (15). (14) and ridge hyperparameters (15), respectively. Notably, while overall covariance is controlled by ! ! through its effect on ! ! !! , each ! ! is given its own L 2 Regularisation hyperparameter, ! ! ! , similar to the LASSO-like "horseshoe"
estimator (Makalic & Schmidt, 2016) . This leads to smaller coefficients (i.e. "noise") being more aggressively shrunk towards zero compared to larger coefficients (i.e. "signal"), compared to regression using scalar Regularisation hyperparameters that lead to constant shrinkage across all !s. ! ! ! and ! ! are sampled from gamma distributions of the form !"##" !, ! , with a posterior mean
Estimates of parameters were taken as means of Gibbs-sampled posterior distributions made from post-burn-in iterations.
Pathway analysis using linear modelling (PALM)
PALM using Reactome (Fabregat et al, 2018; Milacic et al, 2012) pathway annotations was performed as described above using logged fold changes (calculated from the three methods detailed above) as the response variable (!) according to the model for a given Reactome pathway:
Where ! ! and ! ! denote effect sizes due to experimental treatment g and protein p. Residual weights (!) were set to !"# 1,
is the standard error of that protein fold change estimate, ! ! . The code allows the user to limit estimation to only those pathways with a minimum observed number of proteins present in a given dataset; here, we set the minimum to be five.
Empirical Bayes correction of protein variances
All methods included Empirical Bayes correction for stabilising variance estimation (Kammers et al, 2015; Smyth, 2004 (B) Peptide intensities from presumed non-random missing value imputation (Tyanova et al, 2016 ).
(C) Peptide intensities from adaptive multiple imputation.
(D) Imputation on a synthetic incomplete dataset using DGD single imputation, compared to known values from the complete dataset.
(E) Imputation on a synthetic incomplete dataset using AMI, compared to known values from the complete dataset.
Estimated log 2 fold changes in (D) and (E) calculated using BayesENproteomics, actual log 2 fold change = -2. R indicates Pearson's correlation coefficients. 
